1
Clinical Trials associated with Donor derived CAR19 T-cells (National Health & Medical Research Council)A Phase I Study of CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Persistent and Relapsed B-cell Leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation
Start Date04 Dec 2017 |
Sponsor / Collaborator- |
100 Clinical Results associated with Donor derived CAR19 T-cells (National Health & Medical Research Council)
100 Translational Medicine associated with Donor derived CAR19 T-cells (National Health & Medical Research Council)
100 Patents (Medical) associated with Donor derived CAR19 T-cells (National Health & Medical Research Council)
100 Deals associated with Donor derived CAR19 T-cells (National Health & Medical Research Council)